# Safety and Effectiveness of the PXL-Platinum 330 System

> **NCT04401865** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Colorado Eye Consultants/Cornea Consultants of Colorado** · enrollment: 300 (estimated)

## Conditions studied

- Corneal Ectasia
- Keratoconus
- Pellucid Marginal Corneal Degeneration

## Interventions

- **COMBINATION_PRODUCT:** PXL-330 Platinum device for crosslinking with Peschke riboflavin solution

## Key facts

- **NCT ID:** NCT04401865
- **Lead sponsor:** Colorado Eye Consultants/Cornea Consultants of Colorado
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-06-01
- **Primary completion:** 2022-06-30
- **Final completion:** 2023-06-30
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2022-01-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04401865

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04401865, "Safety and Effectiveness of the PXL-Platinum 330 System". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT04401865. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*